Sanofi, a multinational pharmaceutical company, agreed to acquire Origimm, an Austrian privately owned biotechnology company. Financial terms were not disclosed. “The acquisition of Origimm further broadens our vaccines R&D pipeline with a first vaccine candidate against acne, a high medical need for millions of teenagers and adults. Welcoming Origimm within Sanofi expands our area of expertise by bringing extensive know-how in the field of skin microbiome and skin immunology. We look forward to unlocking the full potential of this candidate," Thomas Triomphe, Sanofi Executive Vice President and Global Head.